Effect of COVID-19 Vaccine Inoculation on Pregnancy Outcome during Peri-Pregnancy

doi:10.12280/gjfckx.20230096

Abstract

Abstract:

Objective: To explore the effect of peri-pregnancy vaccination with a novel coronavirus disease 2019 (COVID-19) vaccine on pregnancy outcome and to provide a reference basis for the immunization strategies for peri-pregnant women with COVID-19 vaccine. Methods: The clinical and pregnancy outcome data of 1 987 pregnant women who were hospitalized in the First People′s Hospital of Wuhu and Medical Association Hospital from May 2021 to November 2022 were retrospectively analyzed. According to whether they were vaccinated with COVID-19 vaccine, they were divided into vaccinated group (n=1 346) and unvaccinated group (n=641). The clinical data, pregnancy outcomes, maternal complications and neonatal outcomes of the two groups were analyzed. Results: 1 346 pregnant women were vaccinated with inactivated vaccine in 913 cases (67.83%), recombinant subunit vaccine in 417 cases (30.98%) and adenovirus vector vaccine in 16 cases (1.19%). The proportion of postpartum women in the vaccinated group was higher than that in the unvaccinated group (60.18% vs. 35.22%, P<0.001), and the incidence of hypertension disorder in pregnancy was lower than that in the unvaccinated group (4.61% vs. 7.49%, P=0.009). There was no significant difference between the two groups in the incidence of diabetes in pregnancy, anemia in pregnancy, premature rupture of membranes, amniotic fluid pollution, postpartum hemorrhage, puerperal infection, preterm infants, neonatal malformations, low birth weight infants, admission to the NICU, and the incidence of Apgar score ≤7 points 5 minutes after delivery (all P>0.05). Conclusions: The COVID-19 vaccination in peri-pregnant women is not associated with adverse maternal and infant pregnancy outcomes.

Key words: Pregnancy, SARS-CoV-2, COVID-19 vaccines, Vaccination, Pregnancy outcome

YU Yi-xiang, WEN Ming. Effect of COVID-19 Vaccine Inoculation on Pregnancy Outcome during Peri-Pregnancy[J]. Journal of International Obstetrics and Gynecology, 2023, 50(4): 428-432.

Figures/Tables 3

References 23

[1]	WHO Coronavirus (COVID-19) Dashboard[EB/OL]. [2023-01-04]. https://covid19.who.int.
[2]	Li M, Wang H, Tian L, et al. COVID-19 vaccine development: milestones, lessons and prospects[J]. Signal Transduct Target Ther, 2022, 7(1):146. doi: 10.1038/s41392-022-00996-y. doi: 10.1038/s41392-022-00996-y
[3]	Brillo E, Tosto V, Gerli S, et al. COVID-19 vaccination in pregnancy and postpartum[J]. J Matern Fetal Neonatal Med, 2022, 35(25):7890-7910. doi: 10.1080/14767058.2021.1937991. doi: 10.1080/14767058.2021.1937991
[4]	Vaccination Considerations for People Pregnant or Breastfeeding[EB/OL]. [2023-01-06]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html.
[5]	中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版)[J]. 中华临床感染病杂志, 2021, 14(2):89-90. doi: 10.3760/cma.j.issn.1674-2397.2021.02.002. doi: 10.3760/cma.j.issn.1674-2397.2021.02.002
[6]	谢幸, 苟文丽. 妇产科学[M]. 8版. 北京: 人民卫生出版社, 2014:265-268.
[7]	中华医学会围产医学分会. 备孕、妊娠和哺乳期妇女新型冠状病毒疫苗接种的专家建议[J]. 中华围产医学杂志, 2022, 25(1):13-17. doi: 10.3760/cma.j.cn113903-20211204-01003. doi: 10.3760/cma.j.cn113903-20211204-01003
[8]	Kalafat E, Heath P, Prasad S, et al. COVID-19 vaccination in pregnancy[J]. Am J Obstet Gynecol, 2022, 227(2):136-147. doi: 10.1016/j.ajog.2022.05.020. doi: 10.1016/j.ajog.2022.05.020 pmid: 35568189
[9]	曹羽明, 陈慧君, 郭娟娟, 等. COVID-19孕妇母婴结局的系统综述[J]. 中华围产医学杂志, 2020, 23(7):447-455. doi: 10.3760/cma.j.cn113903-20200402-00298. doi: 10.3760/cma.j.cn113903-20200402-00298
[10]	Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis[J]. BMJ, 2020, 370:m3320. doi: 10.1136/bmj.m3320. doi: 10.1136/bmj.m3320
[11]	Karasek D, Baer RJ, McLemore MR, et al. The association of COVID-19 infection in pregnancy with preterm birth: A retrospective cohort study in California[J]. Lancet Reg Health Am, 2021, 2:100027. doi: 10.1016/j.lana.2021.100027. doi: 10.1016/j.lana.2021.100027
[12]	Villar J, Ariff S, Gunier RB, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study[J]. JAMA Pediatr, 2021, 175(8):817-826. doi: 10.1001/jamapediatrics.2021.1050. doi: 10.1001/jamapediatrics.2021.1050
[13]	陈延亭, 孙贤华, 李梦茹, 等. 新冠肺炎疫情下孕妇心理健康及应对状况调查[J]. 中国护理管理, 2020, 20(12):1827-1830. doi: 10.3969/j.issn.1672-1756.2020.12.015. doi: 10.3969/j.issn.1672-1756.2020.12.015
[14]	陈奕铭, 杨丽萍, 王燕侠, 等. 某市新型冠状病毒肺炎疫情期间孕妇焦虑抑郁对妊娠结局的影响[J]. 中国计划生育和妇产科, 2022, 14(12):27-31. doi: 10.3969/j.issn.1674-4020.2022.12.07. doi: 10.3969/j.issn.1674-4020.2022.12.07
[15]	Ma Y, Deng J, Liu Q, et al. Effectiveness and Safety of COVID-19 Vaccine among Pregnant Women in Real-World Studies: A Systematic Review and Meta-Analysis[J]. Vaccines (Basel), 2022, 10(2):246. doi: 10.3390/vaccines10020246. doi: 10.3390/vaccines10020246
[16]	韩莹, 和彦苓, 马建新, 等. 孕妇接种流感疫苗对不良妊娠结局影响的Meta分析[J]. 中国疫苗和免疫, 2019, 25(6):710-717. doi: 10.19914/j.cjvi.2019.06.020. doi: 10.19914/j.cjvi.2019.06.020
[17]	Ma Y, Shan Z, Gu Y, et al. Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy[J]. Int J Infect Dis, 2023, 130:196-202. doi: 10.1016/j.ijid.2023.03.017. doi: 10.1016/j.ijid.2023.03.017
[18]	张腾, 孟茜, 魏巍, 等. 妊娠早期接种新型冠状病毒灭活疫苗后的急性不良事件及妊娠结局[J]. 中华围产医学杂志, 2023, 26(3):177-185. doi: 10.3760/cma.j.cn113903-20220830-00791. doi: 10.3760/cma.j.cn113903-20220830-00791
[19]	COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care[EB/OL]. [2023-02-09]. https://www.acog.org/en/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care.
[20]	Hillson K, Clemens SC, Madhi SA, et al. Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination[J]. Lancet, 2021, 398(10312):1683-1684. doi: 10.1016/S0140-6736(21)02282-0. doi: 10.1016/S0140-6736(21)02282-0 pmid: 34688353
[21]	Donders G, Grinceviciene S, Haldre K, et al. ISIDOG Consensus Guidelines on COVID-19 Vaccination for Women before, during and after Pregnancy[J]. J Clin Med, 2021, 10(13):2902. doi: 10.3390/jcm10132902. doi: 10.3390/jcm10132902
[22]	Vaccination Considerations for People Pregnant or Breastfeeding[EB/OL]. [2023-05-23]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html.
[23]	Boettler T, Csernalabics B, Salié H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis[J]. J Hepatol, 2022, 77(3):653-659. doi: 10.1016/j.jhep.2022.03.040. doi: 10.1016/j.jhep.2022.03.040 pmid: 35461912

组别		n		年龄（岁）		分娩前BMI（kg/m²）			孕周（周）		不良孕产史
接种疫苗组		1 346		30.00（27.00，33.00）		26.35（24.02，28.72）			39.00（38.00，40.00）		375（27.86）
未接种疫苗组		641		30.00（27.00，33.00）		26.61（24.26，29.23）			39.00（38.00，40.00）		162（25.27）
Z或χ²				-0.101		-1.789			1.599		1.474
P				0.920		0.072			0.110		0.225
组别	n		剖宫产史		经产妇		终止妊娠方式					活产
组别	n		剖宫产史		经产妇		阴道分娩	剖宫产		其他		活产
接种疫苗组	1 346		195（14.49）		810（60.18）		776（57.65）	544（40.42）		26（1.93）		1 320（98.07）
未接种疫苗组	641		106（16.54）		245（38.22）		370（57.72）	253（39.47）		18（2.81）		623（97.19）
Z或χ²			1.419		84.056		1.604					1.540
P			0.234		<0.001		0.449					0.215

组别		n		年龄（岁）		分娩前BMI（kg/m²）			孕周（周）		不良孕产史
接种疫苗组		1 346		30.00（27.00，33.00）		26.35（24.02，28.72）			39.00（38.00，40.00）		375（27.86）
未接种疫苗组		641		30.00（27.00，33.00）		26.61（24.26，29.23）			39.00（38.00，40.00）		162（25.27）
Z或χ²				-0.101		-1.789			1.599		1.474
P				0.920		0.072			0.110		0.225
组别	n		剖宫产史		经产妇		终止妊娠方式					活产
组别	n		剖宫产史		经产妇		阴道分娩	剖宫产		其他		活产
接种疫苗组	1 346		195（14.49）		810（60.18）		776（57.65）	544（40.42）		26（1.93）		1 320（98.07）
未接种疫苗组	641		106（16.54）		245（38.22）		370（57.72）	253（39.47）		18（2.81）		623（97.19）
Z或χ²			1.419		84.056		1.604					1.540
P			0.234		<0.001		0.449					0.215

组别	n	妊娠期糖尿病	妊娠期高血压疾病	妊娠期贫血	胎膜早破	羊水污染	产后出血	产褥期感染
接种疫苗组	1 346	216（16.05）	62（4.61）	278（20.65）	48（3.57）	179（13.30）	82（6.09）	19（1.41）
未接种疫苗组	641	94（14.66）	48（7.49）	137（21.37）	34（5.30）	105（16.38）	43（6.71）	11（1.72）
χ²		0.631	6.897	0.136	3.315	3.367	0.280	0.271
P		0.427	0.009	0.712	0.069	0.067	0.597	0.603

组别	n	妊娠期糖尿病	妊娠期高血压疾病	妊娠期贫血	胎膜早破	羊水污染	产后出血	产褥期感染
接种疫苗组	1 346	216（16.05）	62（4.61）	278（20.65）	48（3.57）	179（13.30）	82（6.09）	19（1.41）
未接种疫苗组	641	94（14.66）	48（7.49）	137（21.37）	34（5.30）	105（16.38）	43（6.71）	11（1.72）
χ²		0.631	6.897	0.136	3.315	3.367	0.280	0.271
P		0.427	0.009	0.712	0.069	0.067	0.597	0.603

组别	n	早产儿	新生儿形态		新生儿体质量		入住NICU	5 min Apgar评分
组别	n	早产儿	新生儿形态正常	畸形	<2 500 g	≥2 500 g	入住NICU	≤7分	>7分
接种疫苗组	1 320	37（2.80）	1 304（98.79）	16（1.21）	40（3.03）	1 280（96.97）	31（2.35）	21（1.59）	1 299（98.41）
未接种疫苗组	623	26（4.17）	616（98.88）	7（1.12）	27（4.33）	596（95.67）	20（3.21）	15（2.41）	608（97.59）
χ²		2.533	0.028		2.160		1.230	1.553
P		0.111	0.866		0.142		0.267	0.213